Table 3.
Current clinical trials exploring dendritic cell (DC)-based immunotherapy in lung cancer.
| Clinical trial I.D. | Study title | Interventions | Phase |
|---|---|---|---|
| NCT04078269 | MIDRIXNEO-LUNG Dendritic Cell Vaccine in Patients With Non-small Cell Lung Cancer | Biological: Dendritic cell immunotherapyBiological: Antigen-specific DTHBiological: Control DTH | Phase 1 |
| NCT04082182 | MIDRIX4-LUNG Dendritic Cell Vaccine in Patients With Metastatic Non-small Cell Lung Cancer | Biological: Dendritic cell immunotherapyBiological: Antigen-specific DTHBiological: Control DTH | Phase 1 |
| NCT03406715 | Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac – Patients With Small Cell Lung Cancer (SCLC) | Drug: NivolumabDrug: IpilimumabBiological: Dendritic Cell based p53 Vaccine | Phase 2 |
| NCT04199559 | Evaluating Combination Therapy using Autologous Dendritic Cells Pulsed With Antigen Peptides and Nivolumab for Subjects With Advanced Non-small Cell Lung Cancer | Drug: Autologous dendritic cells pulsed with antigen | Phase 1 |
| NCT03371485 | AST-VAC2 Vaccine in Patients With Non-small Cell Lung Cancer | Biological: AST-VAC2 | Phase 1 |
| NCT03360630 | Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC | Biological: Anti-PD-1 plus DC-CIKBiological: Anti-PD-1 alone | Phase 1 |
| NCT03970746 | Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC | Biological: PDC*lung01Drug: Keytruda Injectable ProductDrug: Alimta Injectable Product | Phase 1/2 |
| NCT04147078 | Personalized DC Vaccine for Postoperative Cancer | Biological: DC vaccine subcutaneous administration | Phase 1 |
| NCT03546361 | Intratumoral Administration of CCL21-gene Modified Dendritic Cell With Intravenous Pembrolizumab for Advanced NSCLC | Genetic: Ad-CCL21-DC 1 × 107
Genetic: Ad-CCL21-DC 3 × 107 Genetic: Ad-CCL21-DC 0.05 × 107Drug: Pembrolizumab Genetic: Ad-CCL21-DC ExD |
Phase 1 |
| NCT03735290 | A study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With Advanced Cancer | Biological: ilixadencelDrug: Pembrolizumab | Phase 1/2 |
| NCT03047525 | Study of DC-CTL Combined With CIK for Advanced Solid Tumor | Biological: Cytokine-induced Killer Cells | Phase 1/2 |
| NCT02470468 | Evaluation of Safety and Efficacy of DCVAC/LuCa (immunotherapy of Lung Cancer) in Patients With Metastatic Lung Cancer | Biological: DCVAC add on to SOCBiological: DCVAC and immune enhancers add on to SOCOther: Standard of Care Chemotherapy | Phase 1/2 |
| NCT03871205 | Neoantigen-primed DC Vaccines Therapy for Refractory Lung Cancer | Biological: Neoantigen loaded DC vaccine | Phase 1 |
| NCT04147078 | Personalized DC Vaccine for Postoperative Cancer | Biological: DC vaccine subcutaneous administration | Phase 1 |
Database search (ClinicalTrials.gov) was restricted to clinical trials that are active or will be activated in the near future.